Pharmaceutical

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the…

12 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for…

12 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the…

12 months ago

H1 Welcomes Former FDA Commissioner to Board of Directors, Acquires Ribbon Health, and Unveils 2025 Product Roadmap

Doubles down on its commitment to connecting the world with the right doctors and advancing healthcare innovation and inclusionNEW YORK,…

12 months ago

Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates

– IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical…

12 months ago

Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review

- Achieved 100% revenue growth versus prior year – - Received Investigational Device Exemption approval from the FDA for the…

12 months ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…

12 months ago

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage…

12 months ago

SELLAS Announces Key Business Objectives for 2025

- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009:…

12 months ago

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Industry executive with more than 25 years of finance and strategic leadership experienceBOSTON and SAN DIEGO, Jan. 08, 2025 (GLOBE…

12 months ago